Fit-for-purpose expertise

David Miller, PhD is our Chairman and Chief Executive Officer. Prior to Genesis Research Group, David was Senior Vice President of Global Market Access at Biogen. He previously founded a consultancy delivering business and commercial strategies for biopharmaceutical clients and served as Vice President of Pharmacoeconomics; Managing Director, Asset Executive; and Head of International Operations at Elan. David began his career at GSK, culminating in his role as Vice President of Global Health Outcomes.

Frank A. Corvino, PhD is our Co-Founder and Vice Chairman. A quantitative scientist by training, he has spent the last 15 years advancing the way epidemiology, health outcomes, medical affairs and market access leverage RWE for decision-making and stakeholder communications. He has published frequently in Mathematics, Physics, Statistics and Healthcare, and held academic positions at the City University of New York and Stevens Institute of Technology, where he also received his PhD. He holds an MBA from Columbia Business School.

Sarah Alwardt, PhD is an accomplished executive with extensive experience leading global real-world evidence, research, and healthcare analytics organizations, most recently as President at a leading healthcare consultancy. Prior to that, she launched and grew Ontada, McKesson’s oncology research and real-world evidence business. Sarah combines deep scientific expertise with operational leadership to build high-performing teams, develop innovative client solutions, and deliver meaningful business growth.

Tim Wright leads our Access & Pricing division. An economist and health economist, Tim has worked in the bioscience sector for over 30 years including industry roles in clinical research, EU pricing, and reimbursement, as Head of UK HEOR, Global P&MA Director for two mega-brands, and as Global P&MA Director, early portfolio. Tim also has 18 years in senior executive roles within strategic P&MA consultancies. During his tenure Tim has led over 1,000 engagements across all major therapy areas, as well as rare, orphan, and ultra-orphan diseases.

David Pomerantz is a highly accomplished and versatile commercial executive with over 20 years’ experience in the pharmaceutical industry, most recently as Head of Sales for a leading consultancy. He applies strong strategic, organisational development and execution skills to deliver successful outcomes, working closely with clients and stakeholders as a trusted advisor, and building enduring, high-value partnerships.

For the past decade, Michael has been fostering company growth on a number of ongoing client relationships, supporting the organization from both the UK and US. He works on talent acquisition, company culture, and employee life. He also introduces executable strategies that harmonize business practices to best deliver client solutions.